{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:12:49Z","timestamp":1789456369354,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00228-026-04182-9","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:50:32Z","timestamp":1789019432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response to alemtuzumab-based therapy and long-term survival after allogeneic transplantation in T-Cell prolymphocytic leukemia: a systematic review and meta-analysis of proportions"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3072-9941","authenticated-orcid":false,"given":"Jamiel","family":"Reyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"issue":"12","key":"4182_CR1","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1182\/blood.V78.12.3269.3269","volume":"78","author":"E Matutes","year":"1991","unstructured":"Matutes E, Brito-Babapulle V, Swansbury J, Ellis J, Morilla R, Dearden C et al (1991) Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78(12):3269\u20133274. https:\/\/doi.org\/10.1182\/blood.V78.12.3269.3269","journal-title":"Blood"},{"issue":"3","key":"4182_CR2","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1182\/blood-2012-01-380139","volume":"120","author":"C Dearden","year":"2012","unstructured":"Dearden C (2012) How I treat prolymphocytic leukemia. Blood 120(3):538\u2013551. https:\/\/doi.org\/10.1182\/blood-2012-01-380139","journal-title":"Blood"},{"issue":"14","key":"4182_CR3","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1182\/blood.2019000402","volume":"134","author":"PB Staber","year":"2019","unstructured":"Staber PB, Herling M, Bellido M et al (2019) Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia. Blood 134(14):1132\u20131143. https:\/\/doi.org\/10.1182\/blood.2019000402","journal-title":"Blood"},{"issue":"1","key":"4182_CR4","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1200\/JCO.2002.20.1.205","volume":"20","author":"MJ Keating","year":"2002","unstructured":"Keating MJ, Cazin B, Coutr\u00e9 S et al (2002) Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 20(1):205\u2013213. https:\/\/doi.org\/10.1200\/JCO.2002.20.1.205","journal-title":"J Clin Oncol"},{"issue":"6","key":"4182_CR5","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1182\/blood.v98.6.1721","volume":"98","author":"CE Dearden","year":"2001","unstructured":"Dearden CE, Matutes E, Cazin B et al (2001) High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98(6):1721\u20131726. https:\/\/doi.org\/10.1182\/blood.v98.6.1721","journal-title":"Blood"},{"issue":"22","key":"4182_CR6","doi-asserted-by":"publisher","first-page":"5799","DOI":"10.1182\/blood-2011-08-372854","volume":"118","author":"CE Dearden","year":"2011","unstructured":"Dearden CE, Khot A, Else M et al (2011) Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 118(22):5799\u20135802. https:\/\/doi.org\/10.1182\/blood-2011-08-372854","journal-title":"Blood"},{"issue":"12","key":"4182_CR7","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/cncr.27972","volume":"119","author":"G Hopfinger","year":"2013","unstructured":"Hopfinger G, Busch R, Pflug N et al (2013) Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. Cancer 119(12):2258\u20132267. https:\/\/doi.org\/10.1002\/cncr.27972","journal-title":"Cancer"},{"issue":"4","key":"4182_CR8","first-page":"187e","volume":"28","author":"HS Murthy","year":"2022","unstructured":"Murthy HS, Ahn KW, Estrada-Merly N et al (2022) Outcomes of allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: a contemporary analysis from the Center for International Blood and Marrow Transplant Research. Transpl Cell Ther 28(4):187e. 1- 187.e10","journal-title":"Transpl Cell Ther"},{"issue":"Suppl 1","key":"4182_CR9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood-2024-198075","volume":"144","author":"J Drozd-Sokolowska","year":"2024","unstructured":"Drozd-Sokolowska J, Gras L, Baaij L et al (2024) Long-term outcomes of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia: a study on behalf of the Chronic Malignancies Working Party of the EBMT. Blood 144(Suppl 1):600\u2013601. https:\/\/doi.org\/10.1182\/blood-2024-198075","journal-title":"Blood"},{"issue":"3","key":"4182_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/ejh.12430","volume":"94","author":"T Guillaume","year":"2015","unstructured":"Guillaume T, Beguin Y, Tabrizi R et al (2015) Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French Society for Stem Cell Transplantation (SFGM-TC). Eur J Haematol 94(3):265\u2013269. https:\/\/doi.org\/10.1111\/ejh.12430","journal-title":"Eur J Haematol"},{"issue":"9","key":"4182_CR11","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s00277-019-03759-y","volume":"98","author":"S Yamasaki","year":"2019","unstructured":"Yamasaki S, Nitta H, Kondo E et al (2019) Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation. Ann Hematol 98(9):2213\u20132220. https:\/\/doi.org\/10.1007\/s00277-019-03759-y","journal-title":"Ann Hematol"},{"key":"4182_CR12","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"10","key":"4182_CR13","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.11124\/JBISRIR-D-19-00099","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S et al (2020) Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth 18(10):2127\u20132133. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"issue":"2","key":"4182_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","volume":"23","author":"MH Murad","year":"2018","unstructured":"Murad MH, Sultan S, Haffar S, Bazerbachi F (2018) Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med 23(2):60\u201363. https:\/\/doi.org\/10.1136\/bmjebm-2017-110853","journal-title":"BMJ Evid Based Med"},{"issue":"4","key":"4182_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CJ Clopper","year":"1934","unstructured":"Clopper CJ, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26(4):404\u2013413. https:\/\/doi.org\/10.1093\/biomet\/26.4.404","journal-title":"Biometrika"},{"issue":"7414","key":"4182_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in metaanalyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"7650","key":"4182_CR17","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"4","key":"4182_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22(4):153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"issue":"293","key":"4182_CR19","doi-asserted-by":"publisher","first-page":"293ra102","DOI":"10.1126\/scitranslmed.aaa5079","volume":"7","author":"ZS Hasanali","year":"2015","unstructured":"Hasanali ZS, Saroya BS, Stuart A et al (2015) Epigenetic therapy overcomes treatment resistance in T-cell prolymphocytic leukemia. Sci Transl Med 7(293):293ra102. https:\/\/doi.org\/10.1126\/scitranslmed.aaa5079","journal-title":"Sci Transl Med"},{"issue":"3","key":"4182_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3960\/jslrt.24028","volume":"64","author":"M Yamaguchi","year":"2024","unstructured":"Yamaguchi M, Fukuhara N, Takizawa J et al (2024) Alemtuzumab monotherapy for T-cell prolymphocytic leukemia: an observational study in Japan. J Clin Exp Hematop 64(3):216\u2013222. https:\/\/doi.org\/10.3960\/jslrt.24028","journal-title":"J Clin Exp Hematop"},{"issue":"1","key":"4182_CR21","doi-asserted-by":"publisher","first-page":"100175","DOI":"10.1016\/j.bneo.2025.100175","volume":"3","author":"TM Kadia","year":"2026","unstructured":"Kadia TM, Jain A, Rausch CR, Bataller A, Ravandi F, Jabbour E et al (2026) Phase 1B pilot study of itacitinib with alemtuzumab in patients with T-cell prolymphocytic leukemia. Blood Neoplasia 3(1):100175. https:\/\/doi.org\/10.1016\/j.bneo.2025.100175","journal-title":"Blood Neoplasia"},{"issue":"7","key":"4182_CR22","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/annonc\/mdx163","volume":"28","author":"P Jain","year":"2017","unstructured":"Jain P, Aoki E, Keating M, Wierda WG, O\u2019brien S, Gonzalez GN et al (2017) Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). Ann Oncol 28(7):1554\u20131559. https:\/\/doi.org\/10.1093\/annonc\/mdx163","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"4182_CR23","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1182\/blood-2024-194242","volume":"144","author":"Z Braunstein","year":"2024","unstructured":"Braunstein Z, McLaughlin E, Lingamaneni P, Barta SK, Cao M, Chang T et al (2024) Survival and therapeutic outcomes in T-cell prolymphocytic leukemia (TPLL): a collaborative multi-center study. Blood 144(Suppl 1):982. https:\/\/doi.org\/10.1182\/blood-2024-194242","journal-title":"Blood"},{"issue":"3","key":"4182_CR24","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ajh.27205","volume":"99","author":"VA Vardell","year":"2024","unstructured":"Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens DM (2024) T-cell prolymphocytic leukemia: epidemiology and survival trends in the era of novel treatments. Am J Hematol 99(3):494\u2013496. https:\/\/doi.org\/10.1002\/ajh.27205","journal-title":"Am J Hematol"},{"issue":"1","key":"4182_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41408-025-01428-0","volume":"15","author":"N Wolgast","year":"2025","unstructured":"Wolgast N, Amelunxen E, Fransecky L, Altrock P, Beder T, Ronnacker J et al (2025) Epidemiology and survival of patients with T-cell prolymphocytic leukemia. Blood Cancer J 15(1):206. https:\/\/doi.org\/10.1038\/s41408-025-01428-0","journal-title":"Blood Cancer J"},{"issue":"4","key":"4182_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3109\/10428194.2015.1076930","volume":"57","author":"R Chandran","year":"2016","unstructured":"Chandran R, Gardiner SK, Fenske TS, Spurgeon SE (2016) Survival trends in T cell prolymphocytic leukemia: a SEER database analysis. Leuk Lymphoma 57(4):942\u2013944. https:\/\/doi.org\/10.3109\/10428194.2015.1076930","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"4182_CR27","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/10428194.2023.2243354","volume":"64","author":"M Wasifuddin","year":"2023","unstructured":"Wasifuddin M, Ilerhunmwuwa NP, Wang JC et al (2023) Characteristics and survival outcomes of patients with T cell prolymphocytic leukemia in the United States: 2011\u20132020 analysis of the SEER database. Leuk Lymphoma 64(12):2015\u20132023. https:\/\/doi.org\/10.1080\/10428194.2023.2243354","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"4182_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1182\/blood-2017-05-785683","volume":"130","author":"B Boidol","year":"2017","unstructured":"Boidol B, Kornauth C, van der Kouwe E et al (2017) First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood 130(23):2499\u20132503. https:\/\/doi.org\/10.1182\/blood-2017-05-785683","journal-title":"Blood"},{"issue":"3","key":"4182_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41408-021-00443-1","volume":"11","author":"PJ Hampel","year":"2021","unstructured":"Hampel PJ, Parikh SA, Call TG et al (2021) Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 11(3):47. https:\/\/doi.org\/10.1038\/s41408-021-00443-1","journal-title":"Blood Cancer J"},{"issue":"4","key":"4182_CR30","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1182\/bloodadvances.2023012248","volume":"8","author":"M Herling","year":"2024","unstructured":"Herling M, Dearden C, Zaja F et al (2024) Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv 8(4):842\u2013845. https:\/\/doi.org\/10.1182\/bloodadvances.2023012248","journal-title":"Blood Adv"},{"issue":"6","key":"4182_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/bjh.13175","volume":"168","author":"C Herbaux","year":"2015","unstructured":"Herbaux C, Genet P, Bouabdallah K et al (2015) Bendamustine is effective in T-cell prolymphocytic leukaemia. Br J Haematol 168(6):916\u2013919. https:\/\/doi.org\/10.1111\/bjh.13175","journal-title":"Br J Haematol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04182-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04182-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T06:47:43Z","timestamp":1789454863000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04182-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4182"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04182-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required because this study was based exclusively on published aggregate data and did not involve direct contact with human participants or access to identifiable personal data.","order":1,"name":"Ethics","label":"Ethical considerations","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have read and agree to comply with the Springer AI Policy. During revision, Claude Opus 4.8 (Anthropic, accessed June 2026) was used to support language editing, grammar and style refinement. The authors checked the applicable terms of use for the tool and confirm its suitability for publication-support use. The tool was not used to design the study, select studies, extract data, perform statistical analyses, generate or verify references, create figures or tables, or determine scientific conclusions. The authors reviewed, edited, and verified all revised content, confirmed the originality and accuracy of the content, and take full responsibility for the integrity of the manuscript, including the accuracy of references.","order":6,"name":"Ethics","label":"Generative artificial intelligence (AI) use","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"www.crd.york.ac.uk\/prospero identifier [CRD420261421761].","order":7,"name":"Ethics","label":"Protocol registration","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Reyes and A. Reyes have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"250"}}